Fenebrutinib is a next-gen BTK inhibitor for MS, designed to block inflammatory activity and disease progression. Unlike competitors, Fenebrutinib binds non-covalently and reversibly, offering safety and efficacy advantages. It targets both B-cells and brain immune cells, designed to prevent relapses and slow MS progression.

BBH London